Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

0(0%)

Results Posted

33%(2 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_2

25%

Ph phase_4

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

2(25.0%)

Phase 4Post-market surveillance

6(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Terminated(2)

Detailed Status

Completed6

Withdrawn1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 4

Trials by Phase

Phase 22 (25.0%)

Phase 46 (75.0%)

Trials by Status

completed675%

withdrawn113%

terminated113%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_4

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

NCT00232908

completedphase_2

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

NCT00089492

withdrawnphase_4

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

NCT00461266

completedphase_4

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

NCT00326963

completedphase_4

BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

NCT00337701

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT00232908Phase 4

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

Completed

NCT00089492Phase 2

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

Completed

NCT00461266Phase 4

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

Withdrawn

NCT00326963Phase 4

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

Completed

NCT00337701Phase 4

BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

Completed

NCT00233883Phase 4

WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

Completed

NCT00615134Phase 2

INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.

Completed

NCT00488059Phase 4

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

Terminated

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8